Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 4/20 | 0.48 |
| ▸ | RXRB | P28702 | 4/20 | 0.48 |
| ▸ | RXRG | P48443 | 4/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120834 | 1.00 | IDO1 (0.51) | IDO1RXRARXRBRXRGPSEN1 | |
| SCHEMBL512428 | 0.86 | IDO1 (0.51) | IDO1RXRARXRBRXRGPSEN1 | |
| SCHEMBL30530542 | 0.86 | IDO1 (0.51) | IDO1RXRARXRBRXRGPSEN1 | |
| SCHEMBL14263401 | 0.84 | IDO1 (0.54) | IDO1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3135089 | 0.84 | RXRA (0.53) | RXRARXRBRXRGPSEN1PSEN2 | |
| SCHEMBL30151142 | 0.83 | IDO1 (0.49) | IDO1PTGDR2FFAR4 | |
| SCHEMBL5574328 | 0.82 | CES2 (0.53) | RXRARXRBRXRGPSEN1PSEN2 | |
| SCHEMBL7999435 | 0.82 | RXRA (0.48) | RXRARXRBRXRGPSEN1PSEN2 | |
| SCHEMBL3827119 | 0.81 | RXRA (0.47) | RXRARXRBRXRGPSEN1PSEN2 | |
| SCHEMBL20575945 | 0.81 | RXRA (0.57) | RXRARXRBRXRGPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382488-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-11-21 | — | — | US | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3190109-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2440550-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-11-10 | — | — | US | disclosed |
| US-9434722-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-09-06 | — | — | US | disclosed |
| WO-2016051193-A1 | COMPOUNDS USEFUL AS CSF1 MODULATORS | REDX PHARMA PLC (GB) | 2016-04-07 | — | — | WO | disclosed |
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| CN-101133037-A | Six-membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORP (JP) | 2008-02-27 | — | — | CN | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1487824-B1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
| EP-1487824-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003074515-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | IDO1 723/4885RXRA 3315/4885RXRB 2704/4885 |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | IDO1 9/4885RXRA 4582/4885RXRB 4501/4885 |
| US-20240382488-A1 | NEK7 INHIBITORS | NEK7, NEK11, NEK2 | IDO1 3938/4885RXRA 2874/4885RXRB 3018/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | IDO1 9/4885RXRA 4626/4885RXRB 4538/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | IDO1 9/4885RXRA 4582/4885RXRB 4501/4885 |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | IDO1 3558/4885RXRA 800/4885RXRB 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.